Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8877938 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796331 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(2 months ago) | |
US8404744 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(2 months ago) | |
US8796331
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(3 months from now) | |
US8404744
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(3 months from now) | |
US7468390 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Nov, 2023
(7 months from now) | |
US7468390
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
May, 2024
(1 year, 1 month from now) | |
US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(1 year, 9 months from now) | |
US8101659
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(2 years from now) | |
US9388134 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(3 years from now) | |
US9388134
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
US8877938
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2027
(4 years from now) | |
US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
US11058667 | NOVARTIS PHARMS CORP | Sacubitril-valsartan dosage regimen for treating heart failure |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Feb 16, 2024 |
Pediatric Exclusivity (PED) | Apr 1, 2023 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb...
Dosage: TABLET;ORAL
33
United States
9
Japan
9
European Union
6
Brazil
6
Korea, Republic of
6
China
5
Russia
5
Hungary
5
Norway
4
Denmark
4
Slovenia
4
Portugal
4
Spain
4
New Zealand
3
Israel
3
South Africa
3
Mexico
3
Australia
3
Lithuania
3
Hong Kong
3
Argentina
3
Poland
3
Taiwan, Province of China
3
Canada
2
Morocco
2
Singapore
2
Croatia
2
Peru
2
Ecuador
2
Tunisia
1
IB
1
Austria
1
Jordan
1
Belgium
1
Philippines
1
Germany
1
Colombia
1
Guatemala
1
Cyprus
1
Malaysia
1
Netherlands
1
Chile
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET;ORAL
7
United States
3
Japan
2
Denmark
2
Australia
2
Slovenia
2
Lithuania
2
Hungary
2
Singapore
2
Croatia
2
Portugal
2
Cyprus
2
Spain
2
Korea, Republic of
2
Poland
2
Taiwan, Province of China
2
RS
2
European Union
1
Israel
1
South Africa
1
IB
1
Mexico
1
Saudi Arabia
1
Jordan
1
Hong Kong
1
Morocco
1
Philippines
1
Uruguay
1
Cuba
1
Costa Rica
1
Argentina
1
Brazil
1
Malaysia
1
Dominican Republic
1
Peru
1
Chile
1
Nicaragua
1
China
1
Ecuador
1
EA
1
Canada
1
Tunisia
1
New Zealand
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic